OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Rhea-AI Summary
OPKO Health (NASDAQ: OPK) expanded its financing relationship with HealthCare Royalty (a business of KKR, HCRx) by issuing an additional $125 million of senior secured notes, backed by OPKO’s royalty interests from its mazdutide license with Eli Lilly. The notes mature in 2044, aligned with OPKO’s existing HCRx notes.
According to OPKO, the structure delivers additional non-dilutive capital while capping total payments at 1.5x the funded amount, after which OPKO retains future royalty economics. Mazdutide is commercialized in China by Innovent Biologics, and OPKO began recording related royalty revenue in 2025.
Positive
- $125 million additional senior secured notes provide non-dilutive capital
- Total payments on financed royalties capped at 1.5x the amount funded
- Maturity aligned to 2044 with existing HCRx notes, simplifying structure
- Expanded partnership with HealthCare Royalty, a KKR business
- OPKO retains long-term mazdutide royalty upside after payment cap
Negative
- Senior secured notes are secured by mazdutide royalty interests, encumbering that asset stream
- Obligation to repay up to 1.5x the funded amount from future royalties
- Notes mature in 2044, creating a long-dated financial commitment
News Explained
The additional
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 03 | Private placement | Positive | -0.8% | OPKO participated in Cocrystal's $5 million private placement for antiviral development. |
| Jul 27 | Earnings report | Positive | +33.1% | Q2 revenue increased while operating and net losses narrowed materially year over year. |
| Jul 23 | Earnings date | Neutral | -0.8% | OPKO scheduled its Q2 2026 operating and financial results for July 27. |
| Jun 15 | Preclinical data | Positive | -1.4% | OPK8801001 showed sustained IGF-1 suppression and stronger receptor antagonism in preclinical studies. |
| May 12 | Preclinical data | Positive | -1.8% | MDX3001 demonstrated in vivo CAR-T generation and deep B-cell depletion in animal models. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive preclinical announcements diverged from subsequent declines, while the most recent earnings release aligned with a strong gain.
Key Terms
senior secured notes financial
non-dilutive capital financial
aggregate principal amount financial
royalty interests financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional
The transaction provides OPKO with additional non-dilutive capital while preserving significant long-term participation in the value of the mazdutide franchise. Total payments under the expanded financing structure are capped at 1.5 times the amount funded, after which OPKO retains future royalty economics associated with the financed stream. The structure is intended to unlock immediate value from an emerging royalty stream while maintaining OPKO’s participation in long-term royalty growth.
"This transaction with HCRx further demonstrates our ability to leverage high-quality royalty assets to create non-dilutive financing alternatives for our shareholders," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Mazdutide represents a promising opportunity in China within our partnered product portfolio. By financing a portion of these future royalty interests on attractive terms, we strengthen our balance sheet while retaining meaningful long-term upside."
The product is being commercialized in China by Innovent Biologics, and OPKO receives royalties on commercial sales pursuant to its licensing arrangement with Eli Lilly and Company. OPKO recorded its initial mazdutide royalty revenue during 2025 following commercial launch activities in China.
"We are pleased to further expand our partnership with OPKO," said Clarke Futch, Chairman and CEO of HealthCare Royalty. "OPKO has assembled a unique portfolio of royalty-generating assets, and mazdutide represents an attractive opportunity to invest in a high growth segment in China. We believe this transaction provides a compelling outcome for both organizations and further demonstrates the strength of our relationship."
About HealthCare Royalty
HealthCare Royalty ("HCRx") is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise, and novel and proprietary technologies. For more information, please visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of mazdutide, including whether royalty economics will remain favorable, the growth potential of the market in China, whether the relationship with our commercial and strategic partners will be successful, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading "Risk Factors" in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
Alliance Advisors IR
Vivian Cervantes, 973-873-7724
vcervantes@allianceadvisors.com
